Jennifer Kotsanis
Family · Saint Clairsville, OHNPI 1427495639
Payments from drug & device makers
Across 206 payments — averaging $15.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$255
- Otsuka America Pharmaceutical, Inc.$219
- Axsome Therapeutics, Inc.$137
- Vanda Pharmaceuticals Inc.$92
- Alkermes, Inc.$90
- plus $364 from 9 others
What the payments were for
- Food & beverage$3,05397%
- Education$943%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 149 | $1,989 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $255 |
| Otsuka America Pharmaceutical, Inc. | 11 | $219 |
| Axsome Therapeutics, Inc. | 2 | $137 |
| Vanda Pharmaceuticals Inc. | 5 | $92 |
| Alkermes, Inc. | 5 | $90 |
| Teva Pharmaceuticals USA, Inc. | 5 | $90 |
| Noven Therapeutics, LLC | 5 | $83 |
| Lundbeck LLC | 4 | $59 |
| Johnson & Johnson | 2 | $31 |
| Hologic Sales And Service, LLC | 1 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Corium, LLC | 1 | $17 |
| Almatica Pharma LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$121
How this compares
$3,147 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 23 | $33,007 |
| RexultiBrexpiprazole | 11 | $15,696 |
| Lurasidone Hcl | 11 | $1,287 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 20 | $878 |
| Oxcarbazepine | 18 | $586 |
| Buspirone Hcl | 35 | $499 |
| Divalproex Sodium ErDivalproex Sodium | 18 | $381 |
| Aripiprazole | 24 | $366 |
| Prazosin Hcl | 23 | $227 |
| Quetiapine Fumarate | 15 | $196 |
| Mirtazapine | 25 | $195 |
| Risperidone | 25 | $184 |
| Lamotrigine | 26 | $125 |
| Duloxetine Hcl | 17 | $114 |
| Hydroxyzine Pamoate | 16 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,989 | $33,00723 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $219 | $15,69611 claims |
| Almatica Pharma LLCSertraline Hcl | $15 | $3011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.
Other family in Saint Clairsville
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.